Table 1:

Select Immunotherapy Agents for Prostate Cancer

Class	Agent	Description	Key References
Therapeutic Vaccines	AdV-tk	Adenoviral vector containing the Herpes virus thymidine-kinase gene	Rojas-Martinez et al. [2]
	DCVAC/PCa	Autologous DCs pulsed with killed PSA-positive LNCaP cells	Podrazil et al. [4]
	PROSTVAC	Poxviral-based peptide vaccine encoding the PSA gene + 3 T-cell costimulatory molecules (B7.1, ICAM-1 and LFA-3)	Kantoff et al. [7]
	Sipuleucel-T	Autologous PBMCs activated ex vivo with PA2024 (PAP + GM-CSF)	Kantoff et al. [8]
	BDCA-1BDC-01	Autologous CD1c (BDCA-1+) blood derived DCs loaded with HLA-A*0201-restricted peptides	Prue et al. [9]
	pTVG-HP	Plasmid DNA vaccine encoding PAP cDNA	McNeel et al. [10]
	CV9103 (RNActive)	Self-adjuvanted mRNA vaccine targeting 4 antigens: PSA, PSMA, PSCA and STEAP1	Kübler et al. [11]
	PPV (personalized peptide vaccine)	Personalized vaccine made with up to 4 peptides (such as PSA, PAP, PSMA and MDRP)based on a patient’s unique immunoreactivity profile	Noguchi et al. [12]
	GVAX-PCa	Vaccine comprised of cells from the LNCaP and PC3 cell lines and genetically modified to secrete GM-CSF	Higano et al. [13]
Checkpoint Inhibitors	Ipilimumab	Fully human monoclonal antibody against CTLA-4	Kwon et al. [14]
Misc. Immuno-modulating agents	HER2Bi-aATC	Anti-CD3 ATC armed with anti-HER2 bispecific antibodies (HER2Bi)	Vaishampayan et al. [15]
	Lenalidomide	Immunomodulatory and anti-angiogenic properties	Petrylak et al. [16]
	Tasquinimod	Immunomodulatory and anti-angiogenic properties	Armstrong et al. [17]

^*PSMA= prostate-specific membrane antigen, PSCA=prostate stem cell antigen, STEAP1=six-transmembrane epithelial antigen of the prostate 1